Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, Inc. for $4.10 per share, a 65% premium to last traded price, post-FDA approval of Unloxcyt for metastatic cutaneous ...
Immune checkpoint inhibitors provide durable clinical responses in multiple difficult-to-treat tumor types. The tumor microenvironment, tumor immunogenicity, antigen presentation, and classic ...
Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...
Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle. DNA-damaging chemotherapy and radiation activate functional cellular checkpoints. These ...
Immune checkpoint inhibitors are an important part of the treatment armamentarium for patients with a number of different cancers. Since initial approval of the anti–CTLA-4 antibody ipilimumab for the ...
“adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation.” Not only is Unloxcyt the company’s FDA-approved product, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback